002603 Shijiazhuang Yiling Pharmaceutical

Yiling Pharma Gets Regulatory Nod for Traditional Chinese Medicine

06:26 AM EST, 02/03/2023 (MT Newswires) -- Shijiazhuang Yiling Pharmaceutical (SHE:002603) will hold clinical trials into traditional Chinese medicine Huoxia Ganmao granules after securing the approva

02-03 19:30

Eling Pharmaceutical: It plans not to exceed 3 billion yuan to purchase short-term wealth management products.

02-03 19:05

Eling Pharmaceutical (002603.SZ): Plans to use no more than 3 billion yuan of temporarily idle own funds to purchase short-term wealth management products

Gelonghui, Feb. 3 丨 Eling Pharmaceutical (002603.SZ) announced that on February 3, 2023, the company held the 27th meeting of the 7th board of directors and the 17th meeting of the 7th board of supervisors to review and pass the “Proposal on Using Temporarily Idle Own Funds to Purchase Short-Term Wealth Management Products” respectively. It was agreed that under the circumstances of guaranteeing the company's daily operating capital requirements and effectively controlling investment risks, the company could use part of its temporarily idle own funds to purchase low-risk, high-security, and high-liquidity short-term wealth management products, with an amount not exceeding RMB 3 billion (including the company's 7th session, including the company's 7th session) Decisions of the 24th Board of Directors Meeting

02-03 19:01

Yiling Pharma’s Antibiotic Passes Consistency Test

04:39 AM EST, 02/03/2023 (MT Newswires) -- Shijiazhuang Yiling Pharmaceutical's (SHE:002603) new antibiotics have passed a consistency evaluation by China's National Medical Products Administration, a

02-03 17:40

Eling Pharmaceutical: Roxithromycin tablets passed the consistency evaluation.

02-02 17:24

Eling Pharmaceutical: The company's marketed products do not involve antidiarrheal drugs

02-02 13:03

Eling Pharmaceutical (002603.SZ) had a pre-profit of 2.15 billion to 2,419 billion yuan in 2022, an increase of 60%-80% over the previous year

Gelonghui, Feb. 1 丨 Eling Pharmaceutical (002603.SZ) announced that net profit attributable to shareholders of listed companies in 2022 is expected to be 2,150 million yuan - 2,419 billion yuan, an increase of 60%-80% over the previous year; net profit after deducting non-recurring profit and loss was 2,024 billion yuan - 2,340 billion yuan, an increase of 60%-85% over the same period last year; mainly during the reporting period, sales revenue of the company's leading products increased by a certain margin compared to the same period last year.

02-01 21:55

Eling Pharmaceutical (002603.SZ): Ageratum colic granules approved to carry out clinical trials for gastrointestinal cold attacks and obstruction in moisture

Gelonghui, Feb. 1 丨 Eling Pharmaceutical (002603.SZ) announced that on February 1, 2023, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration. After review, Agastasia cold granules received on November 14, 2022 met the relevant requirements for drug registration, and agreed to carry out clinical trials for gastrointestinal flu attacks and obstruction in moisture. Ageratum cold granules are traditional Chinese medicine compound preparations. The proposed functional treatment is to detoxify and relieve moisture. It is used for gastrointestinal colds and wind attacks. The evidence is blocked in wet moisture. Symptoms include fever, bad wind, nasal congestion and runny nose, headache, drowsiness, and bad

02-01 16:45

Eling Pharmaceutical: Application for clinical trial registration of innovative Chinese medicine, Agaricus cold granules, has been approved

02-01 16:42

Eling Pharmaceutical: Net profit is expected to be 2.15 billion yuan to 2,419 billion yuan in 2022, an increase of 60%-80% over the previous year.

01-30 18:22